HC Wainwright & Co. Reiterates Buy on Coya Therapeutics, Maintains $18 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Coya Therapeutics (NASDAQ: COYA) and maintained a price target of $18. This indicates continued confidence in the company's potential performance in the market.